A recent review further calculates the frequency of KEAP1 and NRF2 mutations for SCLC and NSCLC samples at approximately 25% overall and proposes that the acquisition of ARE-driven enhancement of tumor survival is likely to be the result of an insult that drives tumor promotion or progression rather than the initiation phase [41]. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.